Table 2.
TB costs in USD at different stages of treatment.
| All (N = 212) | ACF (N = 105) | PCF (N = 107) | |||||
|---|---|---|---|---|---|---|---|
| Mean (SD) | Median (IQR) |
Mean (SD) |
Median (IQR) |
Mean (SD) |
Median (IQR) |
p-Value * | |
| Total cost (pre-treatment and treatment) | |||||||
| Direct medical | 201 (374) |
76 (17–226) |
118 (269) |
21 (6–76) |
282 (440) |
141 (75–292) |
<0.001 |
| Direct non-medical | 338 (442) |
236 (106–431) |
298 (337) |
200 (82–391) |
376 (524) |
304 (136–448) |
0.095 |
| Total direct | 536 (683) |
350 (151–668) |
416 (555) |
258 (108–483) |
655 (773) |
429 (250–701) |
<0.001 |
| Indirect | 1052 (1292) |
651 (12–1485) |
979 (1497) |
468 (0–1328) |
1124 (1147) |
925 (75–1559) |
0.067 |
| Total treatment | 1588 (1466) |
1208 (520–218) |
1395 (1498) |
957 (361–1862) |
1779 (1415) |
1359 (724–2482) |
0.006 |
| Pre-Treatment | |||||||
| Direct medical | 113 (276) |
30 (3–97) |
39 (118) |
6 (0–20) |
186 (356) |
82 (40–164) |
<0.001 |
| Direct non-medical | 28 (72) |
4 (1–23) |
12 (37) |
2 (1–5) |
51 (153) |
10 (1–26) |
<0.000 |
| Total direct | 141 (328) |
46 (5–143) |
51 (153) |
10 (1–26) |
229 (420) |
101 (56–198) |
<0.000 |
| Treatment | |||||||
| Direct medical | 87 (212) |
13 (0–78) |
79 (234) |
7 (0–34) |
96 (188) |
35 (0–105) |
0.025 |
| Direct non-medical | 310 (426) |
218 (85–396) |
286 (332) |
188 (66–356) |
334 (502) |
231 (95–419) |
0.294 |
| Total direct | 395 (542) |
245 (102–540) |
365 (528) |
224 (81–409) |
425 (556) |
276 (115–591) |
0.141 |
| Total treatment | 1449 (1393) |
1088 (477–2041) |
1343 (1497) |
888 (317–1693) |
1553 (1282) |
1213 (649–2153) |
0.043 |
Direct medical costs: fees for consultations, diagnostic tests, hospitalizations, and medication; direct non-medical costs: food, travel, and accommodation costs; indirect costs: income loss; monetary values in USD; * Wilcoxon rank-sum test (medians); SD: standard deviation; IQR: interquartile range; significant p-values marked in bold.